Who owns Grace Therapeutics, Inc. (ACER)? Elite investor 13F holders
1 tracked elite investors reported holding Grace Therapeutics, Inc as of 2026-09-30, including Renaissance Technologies LLC. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.
1 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a…
Reported holders and securities, including exits (up to 20)
| Investor | Security | Instrument | Report period | Filed | Value | Quantity | Units | Change | Source |
|---|---|---|---|---|---|---|---|---|---|
| Renaissance Technologies LLC | GRACE THERAPEUTICS INC | SHARE | 2026-09-30 | 2026-11-12 00:00:00 | 400188.00 USD | 186134.000000 | Shares | buy | Original filing |
Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.
This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.